Johnson & Johnson vs Novartis
Johnson & Johnson (JNJ), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Johnson & Johnson is worth $675.9B on the stock market and Novartis $302B: Johnson & Johnson is valued at 2.2 times as much. Johnson & Johnson trades at 42.6 times earnings and Novartis at 30.5. Over the past year Johnson & Johnson's share price has moved +41.3% and Novartis's +25.1%.
Key facts
- Johnson & Johnson market value
- $675.9B
- Novartis market value
- $302B
- Johnson & Johnson P/E
- 42.6
- Novartis P/E
- 30.5
- Johnson & Johnson revenue
- $94.2BFY to 2025-12-28
- Novartis revenue
- $54.5BFY to 2025-12-31
- Superinvestors holding both
- 8
Market values as of .
| Measure | Johnson & Johnson | Novartis |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-28 | 2025-12-31 |
| Size | ||
| Market cap | $675.9Bhigher | $302Blower |
| Revenue | $94.2Bhigher | $54.5Blower |
| Earnings | $26.8Bhigher | $14Blower |
| Employees | 138,200higher | 75,267lower |
| Total assets | $199.2Bhigher | $110.9Blower |
| Valuation | ||
| P/E | 42.6higher | 30.5lower |
| P/S | 7.2higher | 5.5lower |
| P/B | 8.3 | — |
| Dividend yield | 1.87% | — |
| Profitability | ||
| Operating margin | — | 32.4% |
| Balance sheet | ||
| Net assets | $81.5Bhigher | $46.1Blower |
| Total liabilities | $117.7Bhigher | $64.4Blower |
| Total debt | $47.9Bhigher | $28.7Blower |
| Cash on hand | $19.7Bhigher | $11.4Blower |
| Price change | ||
| Today | -0.62%lower | -0.17%higher |
| 1 year | +41.3%higher | +25.1%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (8)
- Tweedy, Browne team4.1% / 0.8%
- Jeremy Grantham (co-founder)4.0% / 0.1%
- Ken Fisher1.1% / 0.7%
- Andrew Spokes0.7% / 0.2%
- Charles Brandes (founder)0.3% / 0.2%
- Murray Stahl0.1% / <0.1%
- Rajiv Jain<0.1% / <0.1%
- Dodge & Cox team<0.1% / 0.1%
Johnson & Johnson only (15)
- Stephen Yacktman4.0%
- Mark Boyar2.6%
- Tom Gayner1.3%
- Fred DiSanto1.1%
- Mairs & Power team0.9%
- Ray Dalio (founder)0.7%
- Cliff Asness0.3%
- Ken Griffin0.2%
- Mario Gabelli0.2%
- George Soros0.1%
- Jensen team0.1%
- John Rogers0.1%
- Christopher Bloomstran<0.1%
- Howard Gleicher<0.1%
- Thomas Russo<0.1%
Novartis only (5)
- Primecap team0.6%
- Brandon Haley0.4%
- Larry Robbins0.3%
- Thomas Kahn0.3%
- Lee Ainslie<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Johnson & Johnson / Novartis). Who owns JNJ · Who owns NVS
More on Johnson & Johnson
Further comparisons
Johnson & Johnson against its closest peers
Novartis against its closest peers
Learn
Questions and answers
Which is bigger, Johnson & Johnson or Novartis?
By market value, Johnson & Johnson is the larger: $675.9B against $302B for Novartis. By revenue in its latest fiscal year, Johnson & Johnson is the larger: $94.2B against $54.5B for Novartis.
Which has the higher P/E ratio?
Johnson & Johnson: 42.6, against 30.5 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has more debt?
Johnson & Johnson: $47.9B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Johnson & Johnson and Novartis?
In their latest 13F filings, Tweedy, Browne team, Jeremy Grantham (co-founder), Ken Fisher, Andrew Spokes, Charles Brandes (founder), Murray Stahl, Rajiv Jain and Dodge & Cox team hold both.
Cite this page
Funkfolio, “Johnson & Johnson vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/jnj-vs-nvs
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.